Publication
Judicial Review: what do you need to know?
Judicial review allows a party to challenge the lawfulness of a decision or action made by a public body.
Global | Publication | April 2018
On December 14, 2017, the Commissioner of the US Food and Drug Administration (FDA), Dr. Scott Gottlieb, posted Looking ahead: Some of FDA’s major policy goals for 2018 on FDA’s blog, FDA Voice, and discussed FDA’s policy agenda published on the Unified Agenda of Federal Regulatory and Deregulatory Actions (Unified Agenda), which provides the public with insight into regulations under development or review throughout the federal government. In the Unified Agenda, FDA outlines some of its efforts to modernize its approach and improve its efficiency, while protecting and promoting the public health and upholding FDA’s “gold standard” for regulatory decisionmaking. Gottlieb discussed the FDA’s contributions to the Fall 2017 Unified Agenda, which address a number of areas of policymaking underway at the agency, and are directly aligned with the FDA’s major priorities
Gottlieb stressed that just because a previously identified regulation does not appear on this Unified Agenda submission does not necessarily mean the agency does not consider it a priority or will not continue to consider it moving forward. Over the next year, the FDA will address many additional priority areas,including efforts to reduce the cost of drugs by encouraging competition, spur innovation across medical products, give consumers access to clear and consistent nutrition information, create greater regulatory efficiencies in bringing products to market, and put a dent in the country’s opioid addiction crisis. The Health Law Pulse will continue to monitor for additional information about the many initiatives identified in the Fall 2017 Unified Agenda. Special thanks to Robert Kantrowitz* for his assistance in drafting this post.
*Law Clerk–not admitted to practice law.
Publication
Judicial review allows a party to challenge the lawfulness of a decision or action made by a public body.
Publication
Welcome to the Q3 2024 edition of the Norton Rose Fulbright International Restructuring Newswire.
Publication
The English Court of Appeal has decided that an artificial neural network (ANN) was not patentable in Comptroller-General of Patents, Designs and Trade Marks v Emotional Perception AI Ltd [2024] EWCA Civ 825 reversing the finding of the lower court (the High Court), and in so doing agreeing with the UK Intellectual Property Office’s (IPO) original rejection of the patent application on the basis of unpatentable subject matter.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2023